Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.

about

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.

Item

http://www.wikidata.org/entity/Q40761630

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Divergent Trends of Anti-JCPyV ...... ng Treatment with Natalizumab.

@en

type

Item

label

Divergent Trends of Anti-JCPyV ...... ng Treatment with Natalizumab.

@en

prefLabel

Divergent Trends of Anti-JCPyV ...... ng Treatment with Natalizumab.

@en

P1476

Divergent Trends of Anti-JCPyV ...... ing Treatment with Natalizumab

@en

P2093

Francesca Sangalli

http://www.w3.org/2001/XMLSchema#string

Lucia Moiola

http://www.w3.org/2001/XMLSchema#string

Massimo Clementi

http://www.w3.org/2001/XMLSchema#string

Nicola De Rossi

http://www.w3.org/2001/XMLSchema#string

Roberta Antonia Diotti

http://www.w3.org/2001/XMLSchema#string

Roberto Burioni

http://www.w3.org/2001/XMLSchema#string

Ruggero Capra

http://www.w3.org/2001/XMLSchema#string

Valeria Caputo

http://www.w3.org/2001/XMLSchema#string

Vittorio Martinelli

http://www.w3.org/2001/XMLSchema#string

P2860

New therapeutic options for HCV infection in the monoclonal antibody era

Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype

Progressive Multifocal Leukoencephalopathy-Associated Mutations in the JC Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c Binding

Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?

Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.

JC polyomavirus mutants escape antibody-mediated neutralization.

P31

scholarly article

P356

10.3390/V8050128

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicasio Mancini

P577

2016-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

302776636

http://www.w3.org/2001/XMLSchema#string

P698

27164128

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4885083

http://www.w3.org/2001/XMLSchema#string